Seminars in Oncology

Papers
(The TQCC of Seminars in Oncology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Clinical efficacy and security analysis of DEB-TACE combined with trans arterial infusion of carrelizumab in the therapy of advanced liver cancer71
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer62
Hepatitis B Virus Reactivation in Cancer Patients Receiving Chemotherapy—A Systematic Review and Meta-Analysis31
Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis31
Unlocking the therapeutic potential of polyphenols: Promising advances and future directions in pancreatic cancer treatment26
Integrated analysis of scRNA-seq and bulk RNA-seq data identifies BHLHE40 as a key gene in pancreatic cancer progression and gemcitabine resistance22
Masthead22
Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review20
Overexpression of CAD in stomach adenocarcinoma tissues and its clinical significance20
Table of Contents20
Influence of Cancer on COVID-19 Incidence, Outcomes, and Vaccine Effectiveness: A Prospective Cohort Study of U.S. Veterans19
Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics19
Role of neoadjuvant pembrolizumab in advanced melanoma17
Editorial Board16
Military exposures and lung cancer in United States Veterans15
Psoas muscle depletion correlates with poor prognosis and compromised immunity in resectable gastric cancer: A multicenter study15
Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung cancer14
Adenocarcinoma on retrorectal cystic hamartoma: An illustrative image for a very rare diagnosis13
Editorial Board13
Editorial Board13
Assessment of PSA responses and changes in the rate of tumor growth -rate with immune checkpoint inhibitors in US Veterans with prostate cancer11
Advancing personalized medicine in LMICs: Predictive indicators for cervical cancer immunotherapy response11
Editorial Board11
Masthead11
Editorial Board10
Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer10
Masthead10
Prostate cancer: Evolution of multiparametric MRI PI-RADS v2.1 toward biparametric MRI S-PI-RADS10
Impact of the COVID-19 Pandemic on the Wellbeing of International Oncology and Hematology Fellows at the Princess Margaret Cancer Center (PMCC)10
Masthead10
The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review10
Acute liver failure secondary to malignant infiltration: A single center experience9
The nervous system in prostate cancer: A basic science and clinical perspective9
Lactylation in radiosensitivity regulation: Mechanistic insights and recent advances9
Role of Magnolol in gastrointestinal cancers: recent trends and future perspectives9
Hexokinases in gastrointestinal cancers: From molecular insights to therapeutic opportunities8
Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironment8
Mapping the epidemiology of cancer-related anemia: A systematic scoping review of global prevalence and incidence8
The effects of microbiota-derived short-chain fatty acids on T lymphocytes: From autoimmune diseases to cancer8
Surgery for early-stage lung cancer with video-assisted thoracoscopic surgery versus open thoracotomy: A narrative review7
The challenges of selecting cancer medicines for the WHO Essential Medicines List with the elephant in the room: A path forward7
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population7
Biomarkers and the microbiome in the detection and treatment of early-stage non-small cell lung cancer7
Screening Adherence for Second Primary Malignancies in Breast Cancer Survivors: Behaviors, Facilitators, and Barriers to Enhance Quality Care7
Editorial Board7
Barriers and facilitators to lung cancer screening and follow-up6
Masthead6
MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeutics6
Multiple myeloma: Insights into underlying mechanisms, advances in diagnostic and therapeutic modalities6
A narrative review of the principal glucocorticoids employed in cancer6
Exosomal circular RNAs as drivers of temozolomide resistance in glioblastoma: Mechanisms and implications5
Primary adrenal insufficiency induced by immune checkpoint inhibitors: biological, clinical, and radiological aspects5
Colorectal cancer in Ethiopia: Epidemiological trends, diagnostic and laboratory capacities, and challenges5
outside front cover5
Risk of Intensive Care Unit Admission after Immune Checkpoint Inhibitor Use in Cancer5
Tumor tough, therapy smarter: Rethinking CAR-T for pancreatic cancer5
High tumor mutation burden mitigates the negative impact of chemotherapy history on immune checkpoint blockade therapy5
Recent updates on novel heterocyclic scaffolds of anticancer potential as emerging tubulin inhibitors5
Unveiling the role of RAI14 in cancer: Biological significance and translational perspectives4
Masthead4
Metabolism at the core of melanoma: From bioenergetics to immune escape and beyond4
Advances and challenges in cancer immunotherapy: Strategies for personalized treatment4
Are we there yet? Gut microbiota for cancer diagnosis, prognosis and treatment4
Cancer genetic mutation prevalence in sub-Saharan Africa: A review of existing data4
Treating advanced lung cancer in older Veterans with comorbid conditions and frailty4
Masthead4
Baicalein and baicalin in cancer therapy: Multifaceted mechanisms, preclinical evidence, and translational challenges4
Editorial Board4
0.07077693939209